Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,033 matching trials from the live ClinicalTrials.gov search.
Conditions
T-Cell Large Granular Lymphocyte Leukemia
Interventions
Oral Azacitidine
Drug
Lead sponsor
Jonathan Brammer
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Charlottesville, Virginia
Conditions
Multiple Myeloma
Interventions
Dasatinib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Conditions
Stroke
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
165
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 111 more
Conditions
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Interventions
Pumitamig, Folfox, Capox, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 29 more
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Completed Phase 2 Interventional Results available

Ipilimumab + Temozolomide in Metastatic Melanoma

NCT01119508
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Renal Transplantation
Interventions
Belatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Springfield, Massachusetts • Detriot, Michigan
Conditions
Prostate Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • South Weymouth, Massachusetts • Londonderry, New Hampshire
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Hepatitis B, Chronic Disease
Interventions
entecavir, adefovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Torrance, California + 7 more
Conditions
Melanoma
Interventions
Nivolumab, HF10
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Advanced Renal Cell Carcinoma (aRCC)
Interventions
Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy
Combination Product
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dublin, Ohio
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Malignant Melanoma
Interventions
BMS-936558 (MDX1106-04), Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • New York, New York + 1 more
Conditions
Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
18F-BMS-986229 Injection, IV 18F-BMS-986229, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumors
Interventions
BMS-986449, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more
Conditions
Congenital Heart Defects, Blood Platelet Disorders
Interventions
Clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 24 Months
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
HIV-Associated Lipodystrophy Syndrome
Interventions
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab+Relatlimab, Nivolumab+Ipilimumab
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
61
States / cities
Muscle Shoals, Alabama • Anchorage, Alaska • Chandler, Arizona + 54 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Anchorage, Alaska • Los Angeles, California • Boise, Idaho + 3 more
Conditions
Rheumatoid Arthritis (RA
Interventions
Peer Coach, Healthy Horizons
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York